ABSTRACT
Detection of fatigue is extremely important in the development of different kinds of preventive systems (such as driver monitoring or operator monitoring for accident prevention). The presence of fatigue for this task should be determined with physiological and objective behavioral indicators. To develop an effective model of fatigue detection, it is important to record a dataset with people in a state of fatigue as well as in a normal state. We carried out data collection using an eye tracker, a video camera, a stage camera, and a heart rate monitor to record a different kind of signal to analyze them. In our proposed dataset, 10 participants took part in the experiment and recorded data 3 times a day for 8 days. They performed different types of activity (choice reaction time, reading, correction test Landolt rings, playing Tetris), imitating everyday tasks. Our dataset is useful for studying fatigue and finding indicators of its manifestation. We have analyzed datasets that have public access to find the best for this task. Each of them contains data of eye movements and other types of data. We evaluated each of them to determine their suitability for fatigue studies, but none of them fully fit the fatigue detection task. We evaluated the recorded dataset by calculating the correspondences between eye-tracking data and CRT (choice reaction time) that show the presence of fatigue.
Subject(s)
Eye Movements , Head Movements , Humans , Heart Rate , Videotape Recording , Reaction Time , Head Movements/physiologyABSTRACT
INTRODUCTION: Changes in mucin production and dyscrinia are common features of inflammation in chronic obstructive pulmonary disease (COPD). Immunohistochemical assessment of MUC-2, MUC-3, MUC-4 expression in the integumentary epithelium, goblet cells, the epithelium of mucous glands and stroma fusiform cells of the bronchial mucosa of COPD patients during an infectious and noninfectious exacerbation was performed. MATERIAL AND METHODS: 30 patients with stage III COPD were enrolled to the study. Patients were divided into 2 groups: group A - 14 patients with non-infectious acute exacerbation of COPD (AECOPD) and group B - 16 patients with infectious AECOPD. Fiberoptic bronchoscopy (FBS) and in vivo bronchial biopsy of bronchial mucosa were implemented to determine the extent and nature of bronchial inflammation. The optical density of specific color in bronchial structures was assessed using immunohistochemical staining to MUC-2, -3 and -4 antigens by means of primary monoclonal antibodies to these proteins, and visualization system Dako EnVision + System, Peroxidase (AEC). RESULTS AND CONCLUSIONS: We detected that in different types of bronchial mucosa epithelial cells, during acute infectious exacerbation, a decrease of antigens MUC-2 and MUC-3 expression of a various degree may occur. This phenomenon in the stroma fusiform cells in AECOPD may be a sign of epithelial-mesenchymal transition, that may play a role in the development of an inflammatory process and progression of fibrosis in COPD.
Subject(s)
Mucin-2/metabolism , Mucin-3/metabolism , Mucin-4/metabolism , Pulmonary Disease, Chronic Obstructive/metabolism , Pulmonary Disease, Chronic Obstructive/pathology , Respiratory Mucosa/metabolism , Bronchi/pathology , Female , Humans , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Function Tests , Respiratory Mucosa/pathology , Respiratory Mucosa/physiopathologyABSTRACT
The aim of our study was to examine the effects of 12-month therapy with recombinant growth hormone (rGH) on the blood antioxidant system in children with growth hormone deficiency (GHD). Total antioxidant capacity (TAC) of plasma was measured by FRAP (ferric reducing antioxidant power or ferric reducing ability of plasma); activities of superoxide dismutase (SOD) and catalase (CAT) in erythrocytes were assessed; non-protein thiols (NT) and ceruloplasmin (CP) levels were also measured. These parameters were determined before and after 12 month of rGH treatment. Eleven treatment-naive prepubertal children with growth hormone deficiency were included in the study. Another 11 prepubertal children comprised a control group. Before rGH treatment, TAC of plasma and NT level in the control group were significantly lower (726 ± 196 vs. 525 ± 166 µmol/L, P = 0.0182 and 0.92 ± 0.18 vs. 0.70 ± 0.22 µmol/ml, P = 0.0319, before and after the therapy, respectively). The only parameter that significantly (19.6 ± 4.7 vs. 14.5 ± 3.4 Units/g Hb, P = 0.0396) exceeded the same in the control group after rGH therapy was SOD activity. However, none of the measured parameters of antioxidant system in GHD children, except for TAC (525 ± 166 vs. 658 ± 115 µmol/L, P = 0.0205), exhibited significant improvement toward the end of the 12-month treatment period, although non-significant changes in CAT activity and CP level were also observed. This work has demonstrated that some parameters of the blood antioxidant system are out of balance and even impaired in GHD children. A 12-month treatment with rGH resulted in a partial improvement of the antioxidant system.
ABSTRACT
A mathematical spatial cancer model of the interaction between a drug and both malignant and healthy cells is considered. It is assumed that the drug influences negative malignant cells as well as healthy ones. The mathematical model considered consists of three nonlinear parabolic partial differential equations which describe spatial dynamics of malignant cells as well as healthy ones, and of the concentration of the drug. Additionally, we assume some phase constraints for the number of the malignant and the healthy cells and for the total dose of the drug during the whole treatment process. We search through all the courses of treatment switching between an application of the drug with the maximum intensity (intensive therapy phase) and discontinuing administering of the drug (relaxation phase) with the objective of achieving the maximum possible therapy (survival) time. We will call the therapy a viable treatment strategy.
Subject(s)
Glioma/epidemiology , Glioma/physiopathology , Neoplasms/epidemiology , Neoplasms/physiopathology , Algorithms , Antineoplastic Agents/therapeutic use , Computer Simulation , Humans , Models, Theoretical , Neoplasms/drug therapyABSTRACT
OBJECTIVE: The authors previously reported an association between the D-amino acid oxidase activator (DAOA)/G30 locus and both schizophrenia and bipolar affective disorder. Given the presumed role of DAOA/G30 in the neurochemistry of psychosis and its localization in a schizophrenia and bipolar affective disorder linkage region (13q34), it was hypothesized that the bipolar affective disorder finding would be mainly due to an association with psychotic features. METHOD: The marker/haplotype associations obtained in a subset of 173 bipolar affective disorder patients with psychotic features were similar to those in the overall patient group, suggesting that stratification on the basis of psychotic features in general might be too crude a procedure. The authors therefore tested whether confining caseness to specific psychotic features would improve detection of genotype-phenotype correlations. RESULTS: In a logistic regression, "persecutory delusions" were found to be the only significant explanatory variable for the DAOA/G30 risk genotype among 21 OPCRIT symptoms of psychosis. The authors therefore tested for association between DAOA/G30 and bipolar affective disorder in the 90 cases with a history of persecutory delusions. Whereas this subset showed strong association (odds ratio=1.83 for the best marker), the remaining larger sample of 165 patients with no such history did not differ from comparison subjects, suggesting that the association between DAOA/G30 and bipolar affective disorder is due to persecutory delusions. This was confirmed in an independent study of 294 bipolar affective disorder patients and 311 comparison subjects from Poland, in which an association between bipolar affective disorder and DAOA/G30 was only seen when case definition was restricted to cases with persecutory delusions. CONCLUSIONS: These data suggest that bipolar affective disorder with persecutory delusions constitutes a distinct subgroup of bipolar affective disorder that overlaps with schizophrenia.
Subject(s)
Bipolar Disorder/classification , Bipolar Disorder/genetics , Carrier Proteins/genetics , Delusions/genetics , Phenotype , Adult , Bipolar Disorder/psychology , Chromosome Mapping , Chromosomes, Human, Pair 13/genetics , Delusions/classification , Delusions/diagnosis , Female , Genetic Linkage , Genetic Markers , Genetic Predisposition to Disease , Genotype , Haplotypes , Humans , Intracellular Signaling Peptides and Proteins , Logistic Models , Male , Middle Aged , Molecular Biology/methods , Paranoid Disorders/classification , Paranoid Disorders/diagnosis , Paranoid Disorders/genetics , Schizophrenia/genetics , Schizophrenic PsychologyABSTRACT
The proline dehydrogenase locus must be considered as a positional and functional candidate in schizophrenia. It is located in the chromosomal region of the velocardiofacial syndrome on 22q11 that is suspected to contain genes relevant to schizophrenia, and is involved in the metabolism of neurotransmitters. Positive association between single-nucleotide polymorphisms at the proline dehydrogenase locus and schizophrenia further supported the role of proline dehydrogenase in the development of schizophrenia. In order to replicate these findings, we analyzed three single-nucleotide polymorphisms in a sample comprising 299 schizophrenic patients and 300 controls. In addition, we assessed whether proline dehydrogenase also contributes to bipolar affective disorder, because chromosome 22q11 is also implicated in bipolar affective disorder. We therefore included 300 patients with bipolar affective disorder. This is the first study on a potential involvement of the proline dehydrogenase locus in bipolar affective disorder. Neither single marker nor haplotype analysis revealed an association between variants at the proline dehydrogenase locus and schizophrenia or bipolar affective disorder.
Subject(s)
Bipolar Disorder/genetics , Polymorphism, Single Nucleotide , Proline Oxidase/genetics , Schizophrenia/genetics , HumansABSTRACT
BACKGROUND: Several lines of evidence indicate that abnormalities in the functioning of the central serotonergic system are involved in the pathogenesis of affective illness. A 44-base-pair insertion/deletion polymorphism in the 5' regulatory region of the serotonin transporter gene (5-HTTLPR), which influences expression of the serotonin transporter, has been the focus of intensive research since an initial report on an association between 5-HTTLPR and depression-related personality traits. Consistently replicated evidence for an involvement of this polymorphism in the etiology of mood disorders, particularly in major depressive disorder (MDD), remains scant. METHODS: We assessed a potential association between 5-HTTLPR and MDD, using the largest reported sample to date (466 patients, 836 control subjects). Individuals were all of German descent. Patients were systematically recruited from consecutive inpatient admissions. Control subjects were drawn from random lists of the local Census Bureau and screened for psychiatric disorders. RESULTS: The short allele of 5-HTTLPR was significantly more frequent in patients than in control subjects (45.5% vs. 39.9%; p = .006; odds ratio = 1.26). CONCLUSIONS: These results support an involvement of 5-HTTLPR in the etiology of MDD. They also demonstrate that the detection of small genetic effects requires very large and homogenous samples.
Subject(s)
Depressive Disorder, Major/genetics , Membrane Glycoproteins/genetics , Membrane Transport Proteins/genetics , Nerve Tissue Proteins/genetics , Polymorphism, Genetic , Adult , Aged , Case-Control Studies , Female , Gene Frequency , Genotype , Humans , Linkage Disequilibrium , Male , Middle Aged , Phenotype , Serotonin Plasma Membrane Transport ProteinsABSTRACT
Demographical and clinical characteristics have been reported to modulate the risk for suicide. This study analysed demographical and clinical characteristics with respect to lifetime suicide attempts in 500 individuals affected with schizophrenic or affective disorders. Suicide attempts were associated with poor premorbid social adjustment, low age at onset, low scores on the "Global Assessment Scale" and childlessness in females.
Subject(s)
Mood Disorders/epidemiology , Mood Disorders/psychology , Schizophrenia/epidemiology , Schizophrenic Psychology , Suicide, Attempted/psychology , Suicide, Attempted/statistics & numerical data , Adult , Age Factors , Age of Onset , Demography , Educational Status , Female , Germany/epidemiology , Humans , Interviews as Topic , Male , Odds Ratio , Parents/psychology , Psychiatric Status Rating Scales , Risk Factors , Sex Factors , Social AdjustmentABSTRACT
We have investigated the gene for dystrobrevin-binding protein 1 (DTNBP1), or dysbindin, which has been strongly suggested as a positional candidate gene for schizophrenia, in three samples of subjects with schizophrenia and unaffected control subjects of German (418 cases, 285 controls), Polish (294 cases, 113 controls), and Swedish (142 cases, 272 controls) descent. We analyzed five single-nucleotide polymorphisms (P1635, P1325, P1320, P1757, and P1578) and identified significant evidence of association in the Swedish sample but not in those from Germany or Poland. The results in the Swedish sample became even more significant after a separate analysis of those cases with a positive family history of schizophrenia, in whom the five-marker haplotype A-C-A-T-T showed a P value of.00009 (3.1% in controls, 17.8% in cases; OR 6.75; P=.00153 after Bonferroni correction). Our results suggest that genetic variation in the dysbindin gene is particularly involved in the development of schizophrenia in cases with a familial loading of the disease. This would also explain the difficulty of replicating this association in consecutively ascertained case-control samples, which usually comprise only a small proportion of subjects with a family history of disease.